Literature DB >> 9209290

Antibodies directed against a variable and neutralizable region of the HTLV-I envelope surface glycoprotein.

D Londos-Gagliardi1, M H Armengaud, F Freund, R Dalibart, E Moze, S Huet, E Legrand, B J Guillemain.   

Abstract

The majority of neutralizing antibodies of HTLV-I are directed against linear epitopes of the envelope surface glycoprotein (gp46) in the immunodominant region 175-199. Although gp46 presents a remarkable degree of conservation, the substitution of the proline at position 192 by a serine is described for 10 isolates among the 54 sequenced ones. This amino acid substitution is known to induce an important change in the orientation of the exposed residues of this region and has drastic consequences on the immunogenicity of the neutralizable epitopes located in this region. We developed monoclonal antibodies directed against epitopes located in this region containing a proline or a serine at position 192. The six monoclonal antibodies obtained recognize the gp46 at the surface of living HTLV-I producing cells, two of them are specific of a 190-197 epitope with a serine at position 192. This demonstrates that the antigenicity of this epitope differs depending on the presence of a proline or a serine at position 192. Altogether, these results demonstrate that the immunodominant neutralizable region 175-199 is antigenically variable.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9209290

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  4 in total

1.  Bovine leukemia virus SU protein interacts with zinc, and mutations within two interacting regions differently affect viral fusion and infectivity in vivo.

Authors:  Jean-Stéphane Gatot; Isabelle Callebaut; Carine Van Lint; Dominique Demonté; Pierre Kerkhofs; Daniel Portetelle; Arsène Burny; Luc Willems; Richard Kettmann
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

Review 2.  Current status of HTLV-1 infection.

Authors:  Toshiki Watanabe
Journal:  Int J Hematol       Date:  2011-10-04       Impact factor: 2.319

Review 3.  A role for an HTLV-1 vaccine?

Authors:  Lee Ratner
Journal:  Front Immunol       Date:  2022-09-08       Impact factor: 8.786

4.  Population-based Seroprevalence of HTLV-I Infection in Golestan Province, South East of Caspian Sea, Iran.

Authors:  Khodaberdi Kalavi; Abdolvahab Moradi; Alijan Tabarraei
Journal:  Iran J Basic Med Sci       Date:  2013-03       Impact factor: 2.699

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.